Balyasny Asset Management
BSX icon

Balyasny Asset Management’s Boston Scientific BSX Stock Holding History

Balyasny Asset Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$405K Sell
9,500
-14,000
-60% -$760K ﹤0.01% 2609
2026
Q1 		$1.47M Sell
23,500
-32,000
-58% -$2.56M ﹤0.01% 1919
2025
Q4 		$5.29M Sell
55,500
-219,900
-80% -$21.6M 0.01% 1362
2025
Q3 		$26.9M Buy
+275,400
New +$28.5M 0.03% 584
2025
Q2 		– Sell
-4,500
Closed -$454K – 2855
2025
Q1 		$454K Sell
4,500
-21,600
-83% -$2.18M ﹤0.01% 2305
2024
Q4 		$2.33M Buy
26,100
+2,000
+8% +$176K ﹤0.01% 1622
2024
Q3 		$2.02M Buy
24,100
+3,000
+14% +$236K ﹤0.01% 1664
2024
Q2 		$1.62M Sell
21,100
-21,000
-50% -$1.54M ﹤0.01% 1605
2024
Q1 		$2.88M Hold
42,100
– – 0.01% 1422
2023
Q4 		$2.43M Buy
+42,100
New +$2.25M ﹤0.01% 1391
2022
Q4 		– Sell
-390,000
Closed -$15.1M – 2800
2022
Q3 		$15.1M Sell
390,000
-2,240,000
-85% -$89.9M 0.05% 523
2022
Q2 		$98M Buy
2,630,000
+2,350,000
+839% +$95.7M 0.32% 46
2022
Q1 		$12.4M Buy
+280,000
New +$12.1M 0.04% 611
2021
Q3 		– Sell
-17,800
Closed -$761K – 1961
2021
Q2 		$761K Buy
+17,800
New +$749K ﹤0.01% 1410
2021
Q1 		– Sell
-100,000
Closed -$3.6M – 1777
2020
Q4 		$3.6M Sell
100,000
-200,000
-67% -$7.21M 0.02% 743
2020
Q3 		$11.5M Buy
300,000
+150,000
+100% +$5.78M 0.08% 345
2020
Q2 		$5.27M Buy
+150,000
New +$5.4M 0.05% 504
2018
Q4 		– Sell
-475,000
Closed -$17.8M – 1418
2018
Q3 		$17.8M Buy
475,000
+45,000
+10% +$1.57M 0.08% 335
2018
Q2 		$14.1M Buy
+430,000
New +$13M 0.06% 393
2017
Q3 		– Sell
-400,000
Closed -$11.1M – 1887
2017
Q2 		$11.1M Buy
+400,000
New +$10.6M 0.05% 510
2016
Q4 		– Sell
-90,072
Closed -$14K – 1348
2016
Q3 		$14K Sell
90,072
-309,928
-77% -$7.39M ﹤0.01% 964
2016
Q2 		$9.35M Buy
+400,000
New +$8.65M 0.06% 367

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Balyasny Asset Management's BSX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Boston Scientific (BSX) stake by 95% in Q2 2026, selling an estimated $69.8M and leaving 71,324 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

Balyasny Asset Management first reported a position in BSX in Q2 2013 and has held it in 37 quarters since. The position peaked at $290M in Q3 2024. 1,479 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Balyasny Asset Management held 71,324 shares of Boston Scientific worth $3.04M as of Q2 2026.
  • Balyasny Asset Management sold 1,284,809 Boston Scientific shares in Q2 2026, an estimated $69.8M.
  • Boston Scientific made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1616 holding.
  • Balyasny Asset Management first reported a position in Boston Scientific in Q2 2013 and has held it in 37 quarters since.
  • Balyasny Asset Management's Boston Scientific position peaked at $290M in Q3 2024.
  • 1,479 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.